Orchid Pharma Key Ratios

NSE: ORCHPHARMA | BSE: 524372

₹944.35

up-down-arrow ₹-0.90 (-0.10%)

As on 15-Oct-2026 10:19IST

Market cap

info icon

₹5,674 Cr

Revenue (TTM)

info icon

₹943 Cr

P/E Ratio

info icon

654.7

P/B Ratio

info icon

3.6

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 28.01 15.57 0.20 9.50 17.37
EBIT -83.04 118.87 -92.44 -60.60 15.40
Net Profit -86.10 156.67 -76.03 -28.48 16.58
EPS -88.52 156.64 -87.52 -54.30 15.47
Book Value -- -- 0.69 80.57 44.08
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 4.382.350.34-3.196.86
Net Margin info 7.043.841.020.829.13
Return on equity info 6.914.051.210.709.79
Return on Capital info 6.475.24--1.118.95
Return on Assets info 4.852.890.550.497.22
Debt to Equity (x) info ----0.250.200.10
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
--
1.11
8.95
9.35
9.11
Peer Median
--
14.03
16.46
15.49
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

1.21

Lower than Peers by 8.73

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
1.21
0.70
9.79
10.23
8.27
Peer Median
9.94
13.45
13.87
14.72
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

0.55

Lower than Peers by 6.99

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
0.55
0.49
7.22
6.84
4.73
Peer Median
7.54
7.94
8.04
7.19
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

0.34

Lower than Peers by 9.00

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
0.34
-3.19
6.86
9.46
4.43
Peer Median
9.34
21.31
10.05
10.28
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

1.02

Lower than Peers by 8.33

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
1.02
0.82
9.13
11.18
8.06
Peer Median
9.35
11.88
9.11
6.78
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
--
4.37
12.39
15.66
16.52
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

0.20

Lower than Peers by 6.19

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
0.20
-11.79
70.57
23.05
19.00
Peer Median
6.38
15.92
7.17
10.56
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-92.44

Lower than Peers by 91.41

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
-92.44
-141.07
23.57
162.82
190.95
Peer Median
-1.03
24.76
12.05
6.17
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-76.03

Lower than Peers by 85.07

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
-76.03
-91.90
37.98
72.07
197.10
Peer Median
9.04
24.25
22.15
27.97
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-87.52

Lower than Peers by 89.57

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
-87.52
-92.63
385.84
60.13
2,474.06
Peer Median
2.05
26.11
8.80
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
--
0.69
29.06
69.82
6.37
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

0.25

Higher than Peers by 0.24

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
0.25
0.20
0.10
0.12
0.48
Peer Median
0.02
0.17
0.03
0.05
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
--
0.06
0.09
0.01
0.20
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

2.45

Lower than Peers by 0.08

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
2.45
1.89
2.16
3.04
1.35
Peer Median
2.53
2.23
2.20
1.93
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.53

Lower than Peers by 0.25

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
1.53
1.13
1.26
2.03
0.73
Peer Median
1.78
1.82
1.72
1.59
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

1.81

Lower than Peers by 8.41

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
1.81
2.12
10.17
6.49
2.68
Peer Median
10.23
11.31
12.28
12.45
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

27.99

Higher than Peers by 1.42

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
27.99
30.93
25.26
23.87
32.32
Peer Median
26.57
30.82
26.23
23.97
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.52

Lower than Peers by 0.15

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
0.52
0.57
0.77
0.59
0.57
Peer Median
0.67
0.72
0.74
0.88
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
--
108.72
71.64
91.49
105.72
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
--
122.82
94.23
109.80
110.01
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
--
147.58
115.57
152.17
162.30
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
--
83.97
50.29
49.12
53.43
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

654.72

Higher than Peers by 602.25

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
654.72
73.48
8.80
57.52
33.87
Peer Median
52.47
52.77
39.17
40.74
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

3.62

Lower than Peers by 1.11

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
3.62
0.48
0.79
4.53
2.28
Peer Median
4.74
5.11
3.61
3.87
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
--
--
--
--
--
Peer Median
0.14
0.12
0.19
0.20
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

88.59

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
88.59
13.50
6.46
36.42
18.03
Peer Median
--
44.86
28.79
25.41
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

5,674

Lower than Peers by 304

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Orchid Pharma
5,674
732
1,189
5,301
1,569
Peer Median
5,978
5,941
3,944
2,959
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...